Influenza virus binding, sialylated oligosaccharide substance and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 8, 2011
Grant Date -
Sep 25, 2003
app pub date -
Jun 20, 2001
filing date -
Jun 21, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The present invention is directed to human influenza virus binding substance containing at least one oligosaccharide chain, which comprises a terminal NeuNAcα6 linked to: (a) a linear or branched polylactosamine type structure consisting of at least three lactosamine residues, a linear sequence optionally containing one or two α3-linked fucose residues in a non-sialylated lactosamine, a branched structure optionally carrying one or more additional NeuNAcα-residues at a terminal position in a branch, and/or (b) a linear or branched structure with two lactosamine and one lactose residue, a linear structure in addition containing one or two α3-linked fucose residues in a non-sialylated lactosamine or lactose, a branched structure optionally carrying one additional NeuNAcα-residue in a terminal position of the branch, or an analog or derivative of said oligosaccharide chain for use in binding of human influenza virus.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully